Granulocyte-colony stimulating factor will be marketed in India for neutropenia in cancer patients.

Abraxis BioScience licensed the right to develop a biosimilar version of G-CSF (granulocyte-colony stimulating factor) in North America and the EU from Biocon.

Therapeutic G-CSF is primarily used for the treatment of neutropenia. Biocon received regulatory approval from the Indian DCGI for the treatment of neutropenia in cancer patients.

Under the terms of the agreement, Biocon will receive an upfront licensing fee and following approval in the licensed territories, royalties from Abraxis BioScience.

Previous articleResearchers Confirm Six New Genetic Variants Related to Heart Disease
Next articleQiagen and Joint Center for Structural Genomics Commercialize Crystallography Tool